Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.30 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.30 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18067526 | 1.00 | L3MBTL1 (0.32) | L3MBTL1NPBWR1ALDH1A1MEN1KMT2A | |
| SCHEMBL18067514 | 0.93 | NPBWR1 (0.33) | NPBWR1ALDH1A1MTNR1AMTNR1B | |
| SCHEMBL18067629 | 0.93 | NPBWR1 (0.33) | NPBWR1ALDH1A1MTNR1AMTNR1B | |
| SCHEMBL18067529 | 0.91 | L3MBTL1 (0.33) | L3MBTL1NPBWR1ALDH1A1HTTKDM4E | |
| SCHEMBL18067623 | 0.91 | L3MBTL1 (0.33) | L3MBTL1NPBWR1ALDH1A1HTTKDM4E | |
| SCHEMBL16559294 | 0.89 | XIAP (0.34) | NPBWR1MEN1KMT2A | |
| SCHEMBL16559350 | 0.89 | XIAP (0.34) | NPBWR1MEN1KMT2A | |
| SCHEMBL18067628 | 0.86 | NPBWR1 (0.33) | NPBWR1MEN1KMT2ATSHR | |
| SCHEMBL18067848 | 0.84 | — | — | |
| SCHEMBL18067627 | 0.83 | NPBWR1 (0.34) | L3MBTL1NPBWR1ALDH1A1MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208045-B2 | Aza-pyridone compounds and uses thereof | ALIOS BIOPHARMA, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| WO-2016145103-A1 | AZA-PYRIDONE COMPOUNDS AND USES THEREOF | ALIOS BIOPHARMA, INC. (US) | 2016-09-15 | — | — | WO | disclosed |
| US-20160264581-A1 | AZA-PYRIDONE COMPOUNDS AND USES THEREOF | Janssen Pharmaceuticals, Inc. | 2016-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208045-B2 | Aza-pyridone compounds and uses thereof | PNPO, ITPA, PDXK | L3MBTL1 4081/4885NPBWR1 3037/4885ALDH1A1 1441/4885 |
| US-20160264581-A1 | AZA-PYRIDONE COMPOUNDS AND USES THEREOF | PNPO, ITPA, PDXK | L3MBTL1 4081/4885NPBWR1 3037/4885ALDH1A1 1441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.